HU9503067D0 - Endotheline receptor antagonists - Google Patents

Endotheline receptor antagonists

Info

Publication number
HU9503067D0
HU9503067D0 HU9503067A HU9503067A HU9503067D0 HU 9503067 D0 HU9503067 D0 HU 9503067D0 HU 9503067 A HU9503067 A HU 9503067A HU 9503067 A HU9503067 A HU 9503067A HU 9503067 D0 HU9503067 D0 HU 9503067D0
Authority
HU
Hungary
Prior art keywords
receptor antagonists
endotheline
endotheline receptor
antagonists
receptor
Prior art date
Application number
HU9503067A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HU9503067D0 publication Critical patent/HU9503067D0/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9503067A 1993-04-27 1994-04-26 Endotheline receptor antagonists HU9503067D0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
HU9503067D0 true HU9503067D0 (en) 1995-12-28

Family

ID=22071916

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9503067A HU9503067D0 (en) 1993-04-27 1994-04-26 Endotheline receptor antagonists
HU9501931A HUT73763A (en) 1993-04-27 1994-04-26 Endothelin receptor antagonists, pharmaceutical compositions contg.them and process to prepare them

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU9501931A HUT73763A (en) 1993-04-27 1994-04-26 Endothelin receptor antagonists, pharmaceutical compositions contg.them and process to prepare them

Country Status (28)

Country Link
EP (1) EP0699069B9 (enExample)
JP (1) JP3346571B2 (enExample)
KR (1) KR100331667B1 (enExample)
CN (1) CN1129428C (enExample)
AP (1) AP573A (enExample)
AT (1) ATE213156T1 (enExample)
AU (1) AU682038B2 (enExample)
BR (1) BR9406572A (enExample)
CA (1) CA2160914A1 (enExample)
CZ (1) CZ291189B6 (enExample)
DE (1) DE69429861T2 (enExample)
DK (1) DK0699069T3 (enExample)
DZ (1) DZ1773A1 (enExample)
ES (1) ES2172535T3 (enExample)
FI (1) FI955103L (enExample)
HU (2) HU9503067D0 (enExample)
IL (1) IL109443A0 (enExample)
MA (1) MA23172A1 (enExample)
NO (1) NO313754B1 (enExample)
NZ (1) NZ266314A (enExample)
PL (1) PL175392B1 (enExample)
PT (1) PT699069E (enExample)
RU (1) RU2130920C1 (enExample)
SG (1) SG49667A1 (enExample)
SI (1) SI9400195B (enExample)
SK (1) SK130595A3 (enExample)
TW (1) TW330204B (enExample)
WO (1) WO1994025013A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
ZA969363B (en) 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
CA2236924A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
EE9800315A (et) 1996-04-04 1999-06-15 Banyu Pharmaceutical Co., Ltd. Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
KR100343832B1 (ko) 1996-08-27 2002-07-20 시오노기세이야쿠가부시키가이샤 크로멘-3-카르복실산 유도체
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
CA2327928A1 (en) * 1998-04-09 1999-10-21 Merck & Co., Inc. Phosphate-mediated cyclization
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
RU2426532C2 (ru) 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
ATE409179T1 (de) 2004-12-21 2008-10-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
WO2006137222A1 (ja) * 2005-06-24 2006-12-28 Tokyo Medical And Dental University 薬剤溶出速度制御方法、及び薬剤溶出性ステント被膜用組成物
WO2007019308A2 (en) 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
FI942059L (fi) * 1991-11-05 1994-07-04 Smithkline Beecham Corp Endoteliinireseptoreiden antagonisteja

Also Published As

Publication number Publication date
PT699069E (pt) 2002-07-31
JPH08510211A (ja) 1996-10-29
JP3346571B2 (ja) 2002-11-18
NO954291L (no) 1995-12-21
SG49667A1 (en) 1998-06-15
AU6775094A (en) 1994-11-21
NO313754B1 (no) 2002-11-25
HUT73763A (en) 1996-09-30
DE69429861D1 (de) 2002-03-21
ES2172535T3 (es) 2002-10-01
WO1994025013A1 (en) 1994-11-10
SK130595A3 (en) 1996-06-05
IL109443A0 (en) 1994-07-31
CZ283595A3 (en) 1996-03-13
HK1012252A1 (en) 1999-07-30
HU9501931D0 (en) 1995-09-28
AP9400636A0 (en) 1994-04-30
FI955103A7 (fi) 1995-10-26
NO954291D0 (no) 1995-10-26
EP0699069B9 (en) 2003-10-22
TW330204B (en) 1998-04-21
BR9406572A (pt) 1996-01-30
AP573A (en) 1997-01-30
EP0699069B1 (en) 2002-02-13
PL175392B1 (pl) 1998-12-31
RU2130920C1 (ru) 1999-05-27
EP0699069A4 (enExample) 1996-04-03
CZ291189B6 (cs) 2003-01-15
DE69429861T2 (de) 2002-09-19
CN1129428C (zh) 2003-12-03
ATE213156T1 (de) 2002-02-15
SI9400195B (sl) 2003-10-31
EP0699069A1 (en) 1996-03-06
PL311272A1 (en) 1996-02-05
NZ266314A (en) 1998-10-28
DZ1773A1 (fr) 2002-02-17
SI9400195A (en) 1994-12-31
DK0699069T3 (da) 2002-05-27
FI955103A0 (fi) 1995-10-26
AU682038B2 (en) 1997-09-18
MA23172A1 (fr) 1994-12-31
CA2160914A1 (en) 1994-11-10
FI955103L (fi) 1995-10-26
CN1124923A (zh) 1996-06-19
KR100331667B1 (ko) 2002-11-08

Similar Documents

Publication Publication Date Title
IL111431A0 (en) Endothelin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
ZA939516B (en) Endothelin receptor antagonists
HU9402486D0 (en) Sulfonamide endotheline antagonists
EP0763035A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS
GB9405317D0 (en) Fibrinogen receptor antagonists
AP9200440A0 (en) Endothelin receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP0475206A3 (en) Angiotensin ii receptor antagonists
IL115613A0 (en) Bicyclic neuropeptide y receptor antagonists
HU9403469D0 (en) Excitatory receptor antagonists
HU913074D0 (en) Fibrinogenic receptor antagonists
SG49667A1 (en) Endothelin receptor antagonists
AU3276293A (en) Angiotensin II receptor antagonists
EP0796098A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
HU9502028D0 (en) Fibrinogen receptor antagonists
EP0801650A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
EP0766684A4 (en) ENDOTHELINE RECEPTOR ANTAGONISTS
GB9320799D0 (en) Fibrinogen receptor antagonists
EP0794779A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
HU9602127D0 (en) Endotheline receptor antagonists
HU9602054D0 (en) Endothelin receptor antagonists
HUP9902817A3 (en) Endothelin receptor antagonists
EP0854721A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS
EP0841926A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS